Galactooligosaccharide supplementation provides protection against citrobacter rodentium-induced colitis without limiting pathogen burden

Microbiology (United Kingdom)

Volumn 164, Issue 2, 2018, Pages 154-162

  Kittana, Hatem ^a   Quintero Villegas, Maria I ^a   Bindels, Laure B ^a   Gomes Neto, João Carlos ^a   Schmaltz, Robert J ^a   Segura Munoz, Rafael R ^a   Cody, Liz A ^a   Moxley, Rodney A ^a   Hostetter, Jesse ^b   Hutkins, Robert W ^a   Ramer Tait, Amanda E ^a  

^a UNIVERSITY OF NEBRASKA LINCOLN   (United States)

^b IOWA STATE UNIVERSITY   (United States)

Author keywords

Anti adherence; Citrobacter rodentium; Conventionally raised mice; Gastrointestinal inflammation; Prebiotics

Indexed keywords

GALACTOSE OLIGOSACCHARIDE; GALACTAN; PREBIOTIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIUM ADHERENCE; CITROBACTER RODENTIUM; COLITIS; COLON TISSUE; CONTROLLED STUDY; DESCENDING COLON; DISEASE SEVERITY; EPITHELIUM CELL; FEMALE; HEP-2 CELL LINE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PATHOGEN LOAD; PRIORITY JOURNAL; SUPPLEMENTATION; ANIMAL; C57BL MOUSE; COLON; DIETARY SUPPLEMENT; DISEASE RESISTANCE; DRUG EFFECT; ENTEROBACTERIACEAE INFECTION; FECES; HUMAN; MICROBIOLOGY; PATHOLOGY; TUMOR CELL LINE; VIRULENCE;

ANIMALS; BACTERIAL ADHESION; CELL LINE, TUMOR; CITROBACTER RODENTIUM; COLITIS; COLON; DIETARY SUPPLEMENTS; DISEASE RESISTANCE; ENTEROBACTERIACEAE INFECTIONS; EPITHELIAL CELLS; FECES; FEMALE; GALACTANS; HUMANS; MICE, INBRED C57BL; PREBIOTICS; VIRULENCE;

EID: 85041857980     PISSN: 13500872     EISSN: 14652080     Source Type: Journal    
DOI: 10.1099/mic.0.000593     Document Type: Article

References (52)

1. Gibson GR, Hutkins R, Sanders ME, Prescott SL, Reimer RA et al. The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics. Nat Rev Gastroenterol Hepatol 2017;14:491-502.
2. Gänzle MG. Enzymatic synthesis of galacto-oligosaccharides and other lactose derivatives (hetero-oligosaccharides) from lactose. Int Dairy J 2012;22:116-122.
3. Bouhnik Y, Flourié B, D’Agay-Abensour L, Pochart P, Gramet G et al. Administration of transgalacto-oligosaccharides increases fecal bifidobacteria and modifies colonic fermentation metabolism in healthy humans. J Nutr 1997;127:444-448.
4. Davis LM, Martínez I, Walter J, Goin C, Hutkins RW. Barcoded pyrosequencing reveals that consumption of galactooligosaccharides results in a highly specific bifidogenic response in humans. PLoS One 2011;6:e25200.
5. Vulevic J, Juric A, Walton GE, Claus SP, Tzortzis G et al. Influence of galacto-oligosaccharide mixture (B-GOS) on gut microbiota, immune parameters and metabonomics in elderly persons. Br J Nutr 2015;114:586-595.
6. Azcarate-Peril MA, Ritter AJ, Savaiano D, Monteagudo-Mera A, Anderson C et al. Impact of short-chain galactooligosaccharides on the gut microbiome of lactose-intolerant individuals. Proc Natl Acad Sci USA 2017;114:E367-E375.
7. Wu S, Grimm R, German JB, Lebrilla CB. Annotation and structural analysis of sialylated human milk oligosaccharides. J Proteome Res 2011;10:856-868.
8. Wong JM, de Souza R, Kendall CW, Emam A, Jenkins DJ. Colonic health: fermentation and short chain fatty acids. J Clin Gastroenterol 2006;40:235-243.
9. van Immerseel F, de Buck J, Pasmans F, Velge P, Bottreau E et al. Invasion of Salmonella enteritidis in avian intestinal epithelial cells in vitro is influenced by short-chain fatty acids. Int J Food Microbiol 2003;85:237-248.
10. Holmes E, Li JV, Marchesi JR, Nicholson JK. Gut microbiota composition and activity in relation to host metabolic phenotype and disease risk. Cell Metab 2012;16:559-564.
11. Flint HJ, Scott KP, Duncan SH, Louis P, Forano E. Microbial degradation of complex carbohydrates in the gut. Gut Microbes 2012; 3:289-306.
12. Defoirdt T, Halet D, Sorgeloos P, Bossier P, Verstraete W. Shortchain fatty acids protect gnotobiotic Artemia franciscana from pathogenic Vibrio campbellii. Aquaculture 2006;261:804-808.
13. Tejero-Sariñena S, Barlow J, Costabile A, Gibson GR, Rowland I. In vitro evaluation of the antimicrobial activity of a range of probiotics against pathogens: evidence for the effects of organic acids. Anaerobe 2012;18:530-538.
14. Shoaf-sweeney KD, Hutkins RW. Adherence, anti-adherence, and oligosaccharides: preventing pathogens from sticking to the host. Adv Food Nutr Res 2008;55:101-161.
15. Quintero M, Maldonado M, Perez-Munoz M, Jimenez R, Fangman T et al. Adherence inhibition of Cronobacter sakazakii to intestinal epithelial cells by prebiotic oligosaccharides. Curr Microbiol 2011; 62:1448-1454.
16. Quintero-Villegas MI, Aam BB, Rupnow J, Sørlie M, Eijsink VG et al. Adherence inhibition of enteropathogenic Escherichia coli by chitooligosaccharides with specific degrees of acetylation and polymerization. J Agric Food Chem 2013;61:2748-2754.
17. Kisiela D, Laskowska A, Sapeta A, Kuczkowski M, Wieliczko A et al. Functional characterization of the FimH adhesin from Salmonella enterica serovar Enteritidis. Microbiology 2006;152:1337-1346.
18. Cleary J, Lai LC, Shaw RK, Straatman-Iwanowska A, Donnenberg MS et al. Enteropathogenic Escherichia coli (EPEC) adhesion to intestinal epithelial cells: role of bundle-forming pili (BFP), EspA filaments and intimin. Microbiology 2004;150:527-538.
19. Shoaf K, Mulvey GL, Armstrong GD, Hutkins RW. Prebiotic galactooligosaccharides reduce adherence of enteropathogenic Escherichia coli to tissue culture cells. Infect Immun 2006;74: 6920-6928.
20. Neeser JR, Koellreutter B, Wuersch P. Oligomannoside-type glycopeptides inhibiting adhesion of Escherichia coli strains mediated by type 1 pili: preparation of potent inhibitors from plant glycoproteins. Infect Immun 1986;52:428-436.
21. Firon N, Ofek I, Sharon N. Interaction of mannose-containing oligosaccharides with the fimbrial lectin of Escherichia coli. Biochem Biophys Res Commun 1982;105:1426-1432.
22. Rodrigues DM, Sousa AJ, Johnson-Henry KC, Sherman PM, Gareau MG. Probiotics are effective for the prevention and treatment of Citrobacter rodentium-induced colitis in mice. J Infect Dis 2012;206:99-109.
23. Chao AW, Bhatti M, Dupont HL, Nataro JP, Carlin LG et al. Clinical features and molecular epidemiology of diarrheagenic Escherichia coli pathotypes identified by fecal gastrointestinal multiplex nucleic acid amplification in patients with cancer and diarrhea. Diagn Microbiol Infect Dis 2017;89:235-240.
24. Izquierdo M, Navarro-Garcia F, Nava-Acosta R, Nataro JP, Ruiz-Perez F et al. Identification of cell surface-exposed proteins involved in the fimbria-mediated adherence of enteroaggregative Escherichia coli to intestinal cells. Infect Immun 2014;82:1719-1724.
25. Kudva IT, Krastins B, Torres AG, Griffin RW, Sheng H et al. The Escherichia coli O157:H7 cattle immunoproteome includes outer membrane protein A (OmpA), a modulator of adherence to bovine rectoanal junction squamous epithelial (RSE) cells. Proteomics 2015;15:1829-1842.
26. Kudva IT, Carter MQ, Sharma VK, Stasko JA, Giron JA. Curli temper adherence of Escherichia coli O157:H7 to squamous epithelial cells from the bovine recto-anal junction in a strain-dependent manner. Appl Environ Microbiol 2017;83:e02594-16.
27. Larzábal M, Zotta E, Ibarra C, Rabinovitz BC, Vilte DA et al. Effect of coiled-coil peptides on the function of the type III secretion system-dependent activity of enterohemorragic Escherichia coli O157: H7 and Citrobacter rodentium. Int J Med Microbiol 2013;303:9-15.
28. Johnson-Henry KC, Pinnell LJ, Waskow AM, Irrazabal T, Martin A et al. Short-chain fructo-oligosaccharide and inulin modulate inflammatory responses and microbial communities in Caco2-bbe cells and in a mouse model of intestinal injury. J Nutr 2014;144: 1725-1733.
29. Mundy R, Macdonald TT, Dougan G, Frankel G, Wiles S. Citrobacter rodentium of mice and man. Cell Microbiol 2005;7:1697-1706.
30. Sellon RK, Tonkonogy S, Schultz M, Dieleman LA, Grenther W et al. Resident enteric bacteria are necessary for development of spontaneous colitis and immune system activation in interleukin-10-deficient mice. Infect Immun 1998;66:5224-5231.
31. Jergens AE, Dorn A, Wilson J, Dingbaum K, Henderson A et al. Induction of differential immune reactivity to members of the flora of gnotobiotic mice following colonization with Helicobacter bilis or Brachyspira hyodysenteriae. Microbes Infect 2006;8:1602-1610.
32. Maaser C, Housley MP, Iimura M, Smith JR, Vallance BA et al. Clearance of Citrobacter rodentium requires B cells but not secretory immunoglobulin A (IgA) or IgM antibodies. Infect Immun 2004; 72:3315-3324.
33. Rathinam VA, Vanaja SK, Waggoner L, Sokolovska A, Becker C et al. TRIF licenses caspase-11-dependent NLRP3 inflammasome activation by gram-negative bacteria. Cell 2012;150:606-619.
34. Lebeis SL, Bommarius B, Parkos CA, Sherman MA, Kalman D. TLR signaling mediated by MyD88 is required for a protective innate immune response by neutrophils to Citrobacter rodentium. J Immunol 2007;179:566-577.
35. Kayagaki N, Warming S, Lamkanfi M, vande Walle L, Louie S et al. Non-canonical inflammasome activation targets caspase-11. Nature 2011;479:117-121.
36. Gibson DL, Ma C, Bergstrom KS, Huang JT, Man C et al. MyD88 signalling plays a critical role in host defence by controlling pathogen burden and promoting epithelial cell homeostasis during Citrobacter rodentium-induced colitis. Cell Microbiol 2008;10:618-631.
37. Dann SM, Spehlmann ME, Hammond DC, Iimura M, Hase K et al. IL-6-dependent mucosal protection prevents establishment of a microbial niche for attaching/effacing lesion-forming enteric bacterial pathogens. J Immunol 2008;180:6816-6826.
38. Alipour M, Lou Y, Zimmerman D, Bording-Jorgensen MW, Sergi C et al. A balanced IL-1β activity is required for host response to Citrobacter rodentium infection. PLoS One 2013;8:e80656.
39. Hall LJ, Murphy CT, Hurley G, Quinlan A, Shanahan F et al. Natural killer cells protect against mucosal and systemic infection with the enteric pathogen Citrobacter rodentium. Infect Immun 2013;81:460-469.
40. Wei OL, Hilliard A, Kalman D, Sherman M. Mast cells limit systemic bacterial dissemination but not colitis in response to Citrobacter rodentium. Infect Immun 2005;73:1978-1985.
41. Medzhitov R, Schneider DS, Soares MP. Disease tolerance as a defense strategy. Science 2012;335:936-941.
42. Simms EL. Defining tolerance as a norm of reaction. Evol Ecol 2000;14:563-570.
43. Schneider DS, Ayres JS. Two ways to survive infection: what resistance and tolerance can teach us about treating infectious diseases. Nat Rev Immunol 2008;8:889-895.
44. Smith AD, Yan X, Chen C, Dawson HD, Bhagwat AA. Understanding the host-adapted state of Citrobacter rodentium by transcriptomic analysis. Arch Microbiol 2016;198:353-362.
45. Petersen A, Heegaard PM, Pedersen AL, Andersen JB, Sørensen RB et al. Some putative prebiotics increase the severity of Salmonella enterica serovar Typhimurium infection in mice. BMC Microbiol 2009;9:245.
46. Ten Bruggencate SJ, Bovee-Oudenhoven IM, Lettink-Wissink ML, van der Meer R. Dietary fructooligosaccharides increase intestinal permeability in rats. J Nutr 2005;135:837-842.
47. Cani PD, Possemiers S, van de Wiele T, Guiot Y, Everard A et al. Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability. Gut 2009;58:1091-1103.
48. Neyrinck AM, van Hée VF, Piront N, de Backer F, Toussaint O et al. Wheat-derived arabinoxylan oligosaccharides with prebiotic effect increase satietogenic gut peptides and reduce metabolic endotoxemia in diet-induced obese mice. Nutr Diabetes 2012;2:e28.
49. Bindels LB, Neyrinck AM, Claus SP, Le Roy CI, Grangette C et al. Synbiotic approach restores intestinal homeostasis and prolongs survival in leukaemic mice with cachexia. Isme J 2016;10:1456-1470.
50. Krumbeck JA, Maldonado-Gomez MX, Martínez I, Frese SA, Burkey TE et al. In vivo selection to identify bacterial strains with enhanced ecological performance in synbiotic applications. Appl Environ Microbiol 2015;81:2455-2465.
51. Monteagudo-Mera A, Arthur JC, Jobin C, Keku T, Bruno-Barcena JM et al. High purity galacto-oligosaccharides enhance specific Bifidobacterium species and their metabolic activity in the mouse gut microbiome. Benef Microbes 2016;7:247-264.
52. Qamar TR, Iqbal S, Syed F, Nasir M, Rehman H et al. Impact of novel prebiotic galacto-oligosaccharides on various biomarkers of colorectal cancer in wister rats. Int J Mol Sci 2017;18:E1785.